Only a few weeks ago, the acquisition of Syncor International by Cardinal Health appeared to be hanging by a thread (SCAN 11/27/02). No more. The deal closed Jan. 1, making Cardinal Health the leading provider of nuclear pharmacy services in the U.S.,
Only a few weeks ago, the acquisition of Syncor International by Cardinal Health appeared to be hanging by a thread (SCAN 11/27/02). No more. The deal closed Jan. 1, making Cardinal Health the leading provider of nuclear pharmacy services in the U.S., according to the company. Syncor's domestic operations will be integrated with Central Pharmacy Services to become the Nuclear Pharmacy Services business of Cardinal Health. Due diligence by Cardinal Health turned up improprieties in certain activities conducted by foreign subsidiaries of Syncor. Subsequent involvement by the U.S. Department of Justice and Securities and Exhange Commission led to a fine and civil penalty. It brought a windfall for Cardinal Health, which adjusted its stock swap purchase price down from $1.1 billion to $750 million.
In the days following the acquisition, Cardinal Health entered a definitive agreement to sell the diagnostic imaging centers previously owned by Syncor to InSight Health Services. Sale of the centers is expected to be finalized through a series of closings beginning about Jan. 31 and running until early May 2003.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.